Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 2 - Caught on Camera

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

Barchart

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

StockNews.com

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Benzinga

3 Stocks the World's Greatest Investors Are Buying up Right Now

Skyrocketing inflation, the Fed’s aggressive interest rate hikes, and growing recession fears have kept the stock market under tremendous pressure lately. Amid the market’s downtrend, the world’s renowned investors are scooping up quality stocks Occidental Petroleum (OXY), Amazon.com (AMZN), and Incyte (INCY). Continue reading….

StockNews.com

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Image sourced from Shutterstock

Benzinga

Twitter And 3 Other Stocks Insiders Are Selling

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga

Global Cord Blood Stock Gains As FDA Announced Clearance To Study Blood Cancer Candidate

The U.S.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

Benzinga

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

4 Analysts Have This to Say About Incyte

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte Corporation's (NASDAQ:INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68. Sales increased 21% Y/Y to $733.24 million, missing the consensus of $750.66 million. The company's operating expenses increased 22% to $616.69 million, with the cost of sales up 45.8%, R&D costs up 15%,…

Benzinga

Incyte: Q1 Earnings Insights

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

How To Attend Incyte Q1 2022 Earnings Conference Call

Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live webcast.

Benzinga

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.

Benzinga

This Favorable Sign Appears On Incyte's Chart

If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

Here's a roundup of top developments in the biotech space over the last 24 hours.

1 2 3

People

Mangeet Kaur BounsMangeet

595 stories

David Tepper

401 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.